J&J reports positive data for Tremfya in low body surface area psoriasis
by
Contributor since / Followers
Contributor since / Followers
4 weeks ago
Michael Vi/iStock Editorial via Getty Images
- Johnson & Johnson (NYSE:JNJ) reported positive data from a Phase 3b study of its drug Tremfya in the treatment of moderate plaque psoriasis affecting low body surface areas such as the scalp, face, skin folds and genitals.
- The study showed 74.2% of people who were given Tremfya achieved either clearance or minimal disease at week 16 versus 12.4% for placebo, according to a statement.
- Currently, Tremfya, a monoclonal antibody therapy, is approved in the U.S. for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis and moderately to severely active ulcerative colitis.